glp 1 deficiency GLP-1 therapy is becoming a widespread pharmaceutical treatment for obesity and type 2 diabetes, but there are side effects. Many users develop deficiencies in critical nutrients like vitamin D, iron, and B Frontiers | GLP-1R in diabetes

doi: 10.1097/TP.0000000000005496.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Learn how weight loss peptides work.

We explore the underlying biological mechanisms, summarize clinical trial evidence, and highlight emerging applications in non-diabetic populations

The use of branded ingredients allows private label partners to leverage established research narratives, ingredient storytelling, and clinical positioning strategies in their marketing materials

GMA105 is a fusion protein that combines GLP-1 fragments with a humanized monoclonal antibody against GLP-1R, while GMA106 includes an antagonistic GIPR antibody fused with GLP-1 molecules, achieving dual receptor activation